Sai Parenterals Limited (SAIPARENT)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 21 July 2026

₹567.9

🎯 Key Takeaways

Sai Parenterals Limited is transitioning from a high-growth phase into a scaling-up stage, marked by aggressive capacity expansion and international market entry following its March 2026 IPO. Management is leveraging strong CDMO momentum and integration of its Australian subsidiary to target ₹750 crores in revenue by FY27, up from ₹381 crores in FY26.
⚠️ Execution risk in scaling up capex projects on time and achieving ₹750 crores revenue target by FY2

Market Cap

₹2,126

✨ Ask AI About SAIPARENT 📊 Interactive Charts

📖 The Story

Sai Parenterals Limited is transitioning from a high-growth phase into a scaling-up stage, marked by aggressive capacity expansion and international market entry following its March 2026 IPO. Management is leveraging strong CDMO momentum and integration of its Australian subsidiary to target ₹750 crores in revenue by FY27, up from ₹381 crores in FY26. The company is in a clear expansion phase, supported by robust top-line growth and margin improvement, though profitability remains early-stage with PAT margin at 1%.

📰 What's Happening

In Q4FY26, the company reported a 166.65% YoY revenue surge to ₹197.93 crores and a 736.04% QoQ PAT jump to ₹13.25 crores, driven by CDMO exports and the integration of its Australian subsidiary. The full-year FY26 revenue rose 140.37% YoY to ₹380.99 crores, supported by 93 new dossiers and long-term CDMO contracts. Management highlighted ongoing expansion into Australia and New Zealand markets and confirmed ₹440 crores of capex through FY27 for capacity enhancement and R&D. The board authorized exploration of organic and inorganic growth opportunities, signaling strategic acceleration post-IPO.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management expressed a forward-looking and confident outlook, targeting ₹750 crores in revenue by FY27 and outlining ₹440 crores of capex to support capacity expansion and R&D. They emphasized ongoing integration of the Australian subsidiary, long-term CDMO contracts, and expansion into new geographies including Australia and New Zealand. The board has authorized exploration of growth opportunities, both organic and inorganic, indicating a strategic focus on scaling the CDMO business. No specific financial targets beyond revenue were provided, but the roadmap is clearly tied to execution of the expansion plan.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Execution risk in scaling up capex projects on time and achieving ₹750 crores revenue target by FY27. 2. Integration risks associated with the Australian subsidiary and Noumed operations, which could impact margins if not fully realized. 3. Early-stage profitability with PAT margin at 1% exposes the company to margin compression risks if cost control slips during expansion. 4. Dependence on CDMO demand and export markets makes it vulnerable to global pharmaceutical slowdowns or regulatory changes in key markets like Australia.

📋 Recent Filings

🧠 Analyst's Read

Sai Parenterals is in a high-investment phase with accelerating growth post-IPO, driven by CDMO expansion and international footprint development. The company's trajectory hinges on successful execution of its capex plan and margin improvement. Investors should monitor quarterly updates for progress on the ₹750 crores revenue target, margin trends, and updates on inorganic growth opportunities. The next few quarters will be critical in validating the scalability of its CDMO model.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on SAIPARENT

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-21.

📡 Get AI alerts when SAIPARENT files new disclosures

Track SAIPARENT filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SAIPARENT — Free

Free account · 2 AI queries/day